Immune-Mediated Hemolytic Anemia

Immune-mediated hemolytic anemia (IMHA) is a life-threatening hematologic disorder characterized by the accelerated destruction of erythrocytes (red blood cells, RBCs) due to the host's own immune system. The immune system mistakenly identifies self-antigens on the RBC membrane as foreign, leading to the production of antibodies (IgG, IgM, or both) and/or complement activation, resulting in either intravascular or extravascular hemolysis. IMHA can be classified as primary (idiopathic) or secondary (triggered by an underlying disease, drug, or toxin). It is one of the most common immune-mediated diseases in dogs and is less frequently diagnosed in cats. The disease can manifest as a peracute, acute, or chronic condition, with clinical signs ranging from mild lethargy to severe collapse and death. Prompt diagnosis and aggressive immunosuppressive therapy are essential for a favorable outcome.

The etiology of IMHA is multifactorial. Primary (idiopathic) IMHA has no identifiable trigger and is believed to result from a breakdown in immune self-tolerance. Secondary IMHA is triggered by various factors, including: - Infectious agents: Mycoplasma haemofelis (feline infectious anemia), Babesia spp., Ehrlichia spp., Anaplasma spp., Leptospira spp., and viral infections (e.g., feline leukemia virus, feline immunodeficiency virus). - Drugs: Penicillins, cephalosporins, sulfonamides, methimazole, propylthiouracil, phenobarbital, and non-steroidal anti-inflammatory drugs (NSAIDs). - Toxins: Onions, garlic, zinc, and copper. - Neoplasia: Lymphoma, leukemia, and hemangiosarcoma. - Vaccination: Rarely, vaccines have been implicated as a trigger. - Other immune-mediated diseases: Systemic lupus erythematosus (SLE), immune-mediated thrombocytopenia (ITP), and polyarthritis. The molecular mechanism involves molecular mimicry, hapten formation, or immune dysregulation, leading to the production of autoantibodies against RBC membrane antigens.

IMHA is most commonly diagnosed in dogs, with an estimated incidence of 0.1-0.2% of the canine population. It is less common in cats. In dogs, certain breeds are predisposed, including Cocker Spaniels, Poodles, Old English Sheepdogs, Irish Setters, and Dachshunds. Female dogs may be slightly overrepresented. The disease can occur at any age but is most frequently seen in middle-aged dogs (mean age 5-6 years). In cats, IMHA is often secondary to Mycoplasma haemofelis infection or underlying neoplasia. There is no clear seasonal pattern, but some studies suggest a higher incidence in spring and fall. Geographic distribution may reflect the prevalence of infectious triggers, such as tick-borne diseases.

The pathophysiology of IMHA involves the immune-mediated destruction of RBCs via two main mechanisms: extravascular hemolysis and intravascular hemolysis. - Extravascular hemolysis: This is the most common mechanism. Antibody-coated RBCs (IgG or IgM) are recognized by macrophages in the spleen, liver, and bone marrow. The macrophages phagocytose the RBCs, leading to their destruction. Partial phagocytosis can result in spherocytosis (in dogs) or ghost cells. The released hemoglobin is metabolized to bilirubin, leading to hyperbilirubinemia and jaundice. - Intravascular hemolysis: This occurs when IgM antibodies or complement (C3b) cause direct lysis of RBCs within the vasculature. This is less common but more severe, leading to hemoglobinemia, hemoglobinuria, and acute renal injury. The immune response is triggered by a loss of self-tolerance, possibly due to altered RBC membrane antigens, polyclonal B-cell activation, or regulatory T-cell dysfunction. The resulting anemia stimulates erythropoiesis, leading to reticulocytosis. However, in some cases, the bone marrow may be unable to compensate, especially if there is concurrent immune-mediated destruction of erythroid precursors (pure red cell aplasia). The systemic inflammatory response can lead to thrombosis, particularly pulmonary thromboembolism, which is a major cause of mortality.

Predisposing factors for IMHA include: - Genetic predisposition: Certain breeds (e.g., Cocker Spaniels, Poodles) have a higher risk, suggesting a genetic component. - Age: Middle-aged dogs are more commonly affected. - Sex: Some studies report a higher incidence in females. - Concurrent infections: Tick-borne diseases (e.g., ehrlichiosis, babesiosis) can trigger IMHA. - Drug exposure: Recent administration of certain drugs (e.g., antibiotics, NSAIDs) may precipitate the disease. - Vaccination: Recent vaccination (within 2-4 weeks) has been associated with an increased risk in some studies. - Stress: Physical or emotional stress may trigger the disease in susceptible individuals. - Underlying neoplasia: Cancer can cause immune dysregulation. - Other immune-mediated diseases: Presence of SLE or ITP increases the risk.

Clinical signs of IMHA vary depending on the severity and rate of hemolysis. Common signs include: - Lethargy and weakness - Pale mucous membranes (pallor) - Icterus (jaundice) of the sclera, mucous membranes, and skin - Tachycardia and tachypnea - Heart murmur (functional flow murmur) - Splenomegaly and/or hepatomegaly - Fever (especially in secondary IMHA) - Hemoglobinuria (dark red or brown urine) - In severe cases: collapse, shock, and death - In peracute cases, signs may be sudden and severe, with acute collapse. - Chronic cases may present with weight loss and intermittent weakness. - Cats may show additional signs such as anorexia and vomiting.

Differential diagnoses for IMHA include: - Blood loss anemia: History of trauma, surgery, or bleeding disorders; presence of hypoproteinemia; no evidence of hemolysis (no icterus, no hemoglobinuria). - Hemolytic anemia due to toxins: Onion or zinc toxicity; history of exposure; presence of Heinz bodies on blood smear. - Microangiopathic hemolytic anemia: Disseminated intravascular coagulation (DIC), vasculitis, or hemangiosarcoma; presence of schistocytes on blood smear. - Inherited RBC defects: Pyruvate kinase deficiency (in Basenjis, Beagles) or phosphofructokinase deficiency (in English Springer Spaniels); chronic hemolytic anemia with no immune-mediated component. - Infectious hemolytic anemia: Babesiosis, ehrlichiosis, or Mycoplasma haemofelis; identification of organisms on blood smear or PCR. - Myelophthisic disease: Leukemia or lymphoma; presence of abnormal cells in blood or bone marrow. - Pure red cell aplasia: Severe non-regenerative anemia with no reticulocytosis; bone marrow biopsy shows absence of erythroid precursors. - Hepatic disease: Can cause icterus and anemia, but no hemolysis; liver enzyme elevations and bilirubinuria. - Renal failure: Can cause anemia due to decreased erythropoietin, but no hemolysis. - Drug-induced hemolysis: History of drug exposure; resolution after drug withdrawal.

The diagnostic algorithm for IMHA involves: 1. Initial assessment: Complete history and physical examination, with attention to mucous membrane color, heart rate, and pulse quality. 2. Minimum database: CBC with blood smear, serum biochemistry profile, and urinalysis. 3. Confirmatory tests: If anemia is present with evidence of regeneration (reticulocytosis) and spherocytosis, IMHA is highly suspected. A positive direct antiglobulin test (Coombs test) confirms the diagnosis, but a negative test does not rule out IMHA. 4. Rule out secondary causes: Perform infectious disease testing (e.g., PCR for Mycoplasma, Babesia, Ehrlichia, Anaplasma), thoracic radiographs, abdominal ultrasound, and possibly bone marrow aspiration if non-regenerative. 5. Assess for complications: Coagulation profile (PT, aPTT, D-dimer) to rule out DIC, and blood gas analysis if respiratory distress. 6. In non-regenerative cases: Bone marrow cytology or biopsy to evaluate for pure red cell aplasia or myelophthisis.

Laboratory findings in IMHA include: - Hematology: Anemia (PCV often < 20%), reticulocytosis (in regenerative cases), spherocytosis (in dogs), polychromasia, anisocytosis, nucleated RBCs, and autoagglutination. In cats, Heinz bodies may be present. Leukocytosis with a left shift may be seen due to inflammation. - Serum biochemistry: Hyperbilirubinemia (predominantly unconjugated), elevated liver enzymes (ALT, ALP) due to hepatic hypoxia or hemolysis, and possibly azotemia if renal injury. - Urinalysis: Hemoglobinuria (positive for blood on dipstick but no RBCs on sediment), bilirubinuria, and high urine specific gravity. - Coagulation profile: May show prolonged PT/aPTT and elevated D-dimer if DIC is present. - Direct antiglobulin test (Coombs test): Positive in 60-70% of cases. - Blood gas analysis: May show metabolic acidosis due to tissue hypoxia. - Biomarkers: C-reactive protein (CRP) may be elevated. In cats, feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) tests should be performed.

Imaging findings in IMHA are non-specific but may include: - Thoracic radiographs: May show mild cardiomegaly due to anemia, or evidence of pulmonary thromboembolism (e.g., oligemia, alveolar infiltrates) in severe cases. - Abdominal ultrasound: Splenomegaly and hepatomegaly are common. Doppler ultrasound may show increased splenic blood flow. - Echocardiography: May be performed to rule out underlying cardiac disease, especially if a heart murmur is present. - Computed tomography (CT): Not routinely used but may be helpful in detecting pulmonary thromboembolism. - Magnetic resonance imaging (MRI): Not indicated in routine cases.

Cytology and histopathology are not typically required for diagnosis but may be helpful in certain situations: - Fine needle aspirate of the spleen or liver: May show extramedullary hematopoiesis and hemosiderin-laden macrophages. - Bone marrow aspiration: In non-regenerative IMHA, bone marrow cytology may show erythroid hyperplasia (if regenerative) or pure red cell aplasia (if non-regenerative). - Histopathology: If a biopsy is performed (e.g., liver), it may show hemosiderosis and extramedullary hematopoiesis.

Treatment of IMHA is multifaceted and includes: - Emergency stabilization: In severe anemia (PCV < 15%) or if clinical signs are life-threatening, blood transfusion (packed RBCs or whole blood) is indicated. Cross-matching is essential to avoid transfusion reactions. - Immunosuppressive therapy: The cornerstone of treatment. Prednisone or prednisolone at immunosuppressive doses (2-4 mg/kg/day PO, divided q12h) is the first-line agent. If there is no response within 48-72 hours, or if the disease is severe, additional immunosuppressants are added, such as: - Azathioprine: 2 mg/kg PO q24h (dogs) or 0.3-0.6 mg/kg PO q48h (cats). - Cyclosporine: 5-10 mg/kg PO q12h. - Mycophenolate mofetil: 10-20 mg/kg PO q12h. - Human intravenous immunoglobulin (hIVIG): 0.5-1.5 g/kg IV over 6-12 hours, once or repeated. - Antithrombotic therapy: To prevent thromboembolism, low-dose aspirin (0.5-1 mg/kg PO q24h) or clopidogrel (1-2 mg/kg PO q24h) may be used. Heparin (200-300 U/kg SC q8h) or low-molecular-weight heparin (e.g., dalteparin 100-150 U/kg SC q8h) may be considered in high-risk patients. - Supportive care: Intravenous fluids (crystalloids) to maintain hydration and renal perfusion, but avoid overhydration. Gastroprotectants (e.g., omeprazole 1 mg/kg PO q12h) may be indicated if corticosteroids are used. Nutritional support if anorexic. - Treatment of underlying cause: If a secondary trigger is identified (e.g., infection, drug), it should be addressed. - Splenectomy: May be considered in refractory cases, but is rarely performed. - Monitoring: Serial PCV, reticulocyte count, and clinical assessment are essential.

The prognosis for IMHA is guarded to good, depending on the severity and response to therapy. Reported mortality rates range from 20-70%. Negative prognostic indicators include: - Severe anemia (PCV < 15%) - Intravascular hemolysis (hemoglobinemia/hemoglobinuria) - Pulmonary thromboembolism - Hyperbilirubinemia - Elevated BUN/creatinine - Lack of reticulocytosis (non-regenerative) - Presence of autoagglutination - High dose of corticosteroids required With aggressive treatment, many dogs survive the initial crisis and can be tapered off immunosuppressive therapy over several months. However, relapses can occur. Cats generally have a poorer prognosis, especially if secondary to FeLV or FIV.

Follow-up care for IMHA includes: - Recheck examinations: Initially every 1-2 weeks until the PCV stabilizes, then monthly. - Serial PCV and reticulocyte counts: To monitor response to therapy. - Blood pressure monitoring: Corticosteroids can cause hypertension. - Urinalysis: To monitor for proteinuria and urinary tract infections. - Tapering of immunosuppressive drugs: Once the PCV is stable (e.g., > 30%) for 2-4 weeks, the corticosteroid dose is gradually reduced over 2-3 months. If other immunosuppressants are used, they may be tapered after corticosteroids are discontinued. - Long-term monitoring: For relapse, especially during stressful events or if the patient is exposed to potential triggers. - In cats, monitor for FeLV/FIV status.

Pearls: - Always perform a blood smear to look for spherocytes and autoagglutination; autoagglutination can be confirmed by adding a drop of saline to the blood. - In cats, Mycoplasma haemofelis is a common cause; treat with doxycycline if suspected. - Blood transfusion should be given slowly and monitored for reactions; use cross-matched blood. - Consider antithrombotic therapy early to prevent fatal thromboembolism. - If the patient is not responding to corticosteroids within 48-72 hours, add a second immunosuppressant. Pitfalls: - Do not use corticosteroids alone in cats with suspected infectious causes. - Avoid over-transfusion; target PCV of 25-30%. - Do not use heparin without monitoring; risk of bleeding. - Do not taper immunosuppressive therapy too quickly; risk of relapse. - Do not forget to rule out underlying causes, especially in cats.

Based on Plumb's Veterinary Drug Handbook, the following protocols are recommended: - Prednisone/Prednisolone: Dogs: 2-4 mg/kg/day PO, divided q12h; Cats: 2-4 mg/kg/day PO, divided q12h. After 2-4 weeks, taper by 25% every 2-4 weeks. - Azathioprine: Dogs: 2 mg/kg PO q24h; Cats: 0.3-0.6 mg/kg PO q48h. Onset of action is 3-5 weeks. - Cyclosporine: Dogs: 5-10 mg/kg PO q12h; Cats: 5-10 mg/kg PO q12h. Monitor blood levels if possible. - Mycophenolate mofetil: Dogs: 10-20 mg/kg PO q12h; Cats: 10-20 mg/kg PO q12h. - Human intravenous immunoglobulin (hIVIG): 0.5-1.5 g/kg IV over 6-12 hours, once; may repeat in 48-72 hours. - Clopidogrel: Dogs: 1-2 mg/kg PO q24h; Cats: 1-2 mg/kg PO q24h. - Aspirin: Dogs: 0.5-1 mg/kg PO q24h; Cats: 10-40 mg/cat PO q72h (use with caution). - Heparin: Dogs: 200-300 U/kg SC q8h; Cats: 200-300 U/kg SC q8h. Monitor aPTT. - Dalteparin: Dogs: 100-150 U/kg SC q8h; Cats: 100-150 U/kg SC q8h. - Doxycycline: For Mycoplasma haemofelis: 5-10 mg/kg PO q12h for 2-3 weeks. - Omeprazole: 1 mg/kg PO q12h for gastrointestinal protection. - Fluid therapy: Balanced crystalloids (e.g., LRS) at maintenance rates (60-100 ml/kg/day) with adjustments based on hydration status.

Key literature and consensus guidelines: - ACVIM consensus statement on the diagnosis and treatment of immune-mediated hemolytic anemia in dogs and cats (2019) provides evidence-based recommendations. - Studies have shown that combination therapy (corticosteroids plus a second immunosuppressant) may improve survival compared to corticosteroids alone. - A retrospective study by Weinkle et al. (2005) found that the use of hIVIG did not significantly improve outcome. - A study by Goggs et al. (2015) reported that thromboembolism is a major cause of death, and antithrombotic therapy is recommended. - The use of fresh frozen plasma has not been shown to be beneficial. - In cats, treatment of underlying Mycoplasma haemofelis with doxycycline is essential. - Prognostic factors have been evaluated in multiple studies; hyperbilirubinemia and elevated creatinine are consistently associated with poorer outcomes. - The use of cyclosporine or mycophenolate as adjunctive therapy has been supported by some studies, but evidence is limited. - A recent meta-analysis (2018) concluded that the addition of azathioprine to corticosteroids did not significantly improve survival. - Overall, early aggressive therapy and careful monitoring are key to improving outcomes.